Sign in

    Edward Tenthoff

    Managing Director and Senior Research Analyst at Piper Jaffray

    Edward Tenthoff is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in biotechnology equity research with a focus on drug discovery, anti-infective and cancer drug development, orphan diseases, and cell therapy. He covers over 100 biotech companies, including Milestone Pharmaceuticals and NextCure, and has issued more than 1,400 stock ratings with notable forecasts such as a 366% return on Poseida Therapeutics and a long-term price target upside average of 54.55%, though his overall success rate stands at 28% with an average return of -17.2%. Tenthoff began his analyst career at Lehman Brothers and Robertson Stephens before joining Piper (formerly Piper Jaffray, now Piper Sandler) in 2003, where he has been recognized as a top stock picker by StarMine and the Wall Street Journal, and is an active leader in health care conferences and inclusion initiatives. He holds a bachelor’s degree in international relations from the University of Pennsylvania and is FINRA-registered, bringing over two decades of industry experience and several honors for excellence in biotech analysis.

    Edward Tenthoff's questions to XOMA Royalty (XOMA) leadership

    Edward Tenthoff's questions to XOMA Royalty (XOMA) leadership • Q4 2015

    Question

    In a follow-up question, Edward Tenthoff of Piper Jaffray asked about XOMA's strategic plans following data readouts, specifically whether the company would seek partnerships or alternative financing to advance its pipeline.

    Answer

    CEO John Varian stated that it is unlikely the company would license out its lead Phase 2 assets at this time, as they believe more value can be built by advancing them independently. He indicated that XOMA would look to monetize other non-core assets to raise capital and fund development, similar to the strategy employed in late 2015.

    Ask Fintool Equity Research AI